Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Unknown 1Completed 1

Sponsor Class

OTHER 14INDUSTRY 3NIH 2NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2Thoracic 1Other solid neoplasm 1Breast 1

Conditions

Endometrial Neoplasms 2Mesothelioma, Malignant 1Liver Neoplasms 1FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma 1Carcinoma, Hepatocellular 1Breast Neoplasms 1

Interventions

Specimen Handling 10Magnetic Resonance Spectroscopy 9Carboplatin 9Taxes 7Paclitaxel 7Biopsy 7temsirolimus 6Trastuzumab 5Sirolimus 5pembrolizumab 4Radiotherapy 4olaparib 3Nivolumab 3Interleukin-12 Subunit p35 3Bevacizumab 3pertuzumab 2palbociclib 2ipatasertib 2binimetinib 2aldesleukin 2X-Rays 2Thalidomide 2Reverse Transcriptase Polymerase Chain Reaction 2Oxaliplatin 2Megestrol Acetate 2Interleukin-12 2Immunoglobulin G 2Fluorouracil 2Docetaxel 2Disulfides 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NIH × Endometrial Neoplasms × Megestrol Acetate × Clear all
NCT00729586 2019-07-23

Temsirolimus With or Without Megestrol Acetate and Tamoxifen Citrate in Treating Patients With Advanced, Persistent, or Recurrent Endometrial Cancer

National Cancer Institute (NCI)

Phase 2 Completed
73 enrolled 13 charts
Gynecologic

Endometrial Neoplasms

NCT00002465 2013-11-06

High-Dose Megestrol in Treating Patients With Metastatic Breast Cancer, Endometrial Cancer, or Mesothelioma

National Cancer Institute (NCI)

Phase 1/2 Unknown
BreastGynecologicOther solid neoplasmThoracic

Mesothelioma, Malignant, Breast Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡